Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)
Hong Kong
· Delayed Price · Currency is HKD 1.600
-0.070 (-4.19%)
Apr 17, 2025, 2:18 PM HKT
HKG:8049 Revenue
In the year 2024, Jilin Province Huinan Changlong Bio-pharmacy Company had annual revenue of 881.16M CNY with 4.71% growth. Jilin Province Huinan Changlong Bio-pharmacy Company had revenue of 244.03M in the quarter ending December 31, 2024, a decrease of -1.88%.
Revenue
881.16M CNY
Revenue Growth
+4.71%
P/S Ratio
0.96
Revenue / Employee
1.18M CNY
Employees
745
Market Cap
896.40M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 881.16M | 39.61M | 4.71% |
| Dec 31, 2023 | 841.55M | -41.00K | -0.00% |
| Dec 31, 2022 | 841.59M | 136.13M | 19.30% |
| Dec 31, 2021 | 705.46M | 83.21M | 13.37% |
| Dec 31, 2020 | 622.25M | -23.64M | -3.66% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |